Taking Stock of the Evolving Treatment Landscape for Acute GvHD in HSCT: Proceedings from a Clinical Olympics℠

Program Overview

Allogeneic hematopoietic cell transplantation is a potentially curative therapy for many malignant and nonmalignant hematologic diseases. Acute graft-versus-host disease (aGVHD) is a common complication associated with this procedure that can affect up to 50% of patients. Patients with aGVHD commonly present with a maculopapular rash, nausea, vomiting, profuse watery diarrhea and abdominal cramping, and hyperbilirubinemia with jaundice. In this educational activity, renowned GVHD experts discuss staging/grading of GVHD, current prophylactic and treatment strategies, and emerging agents.

Credit Expired

Target Audience

Hematology, hematology/oncology, and transplantation clinicians

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Apply available therapies and guidelines for acute graft-versus-host disease (aGVHD) management in hematopoietic stem cell transplantation (HSCT) patients
  • Examine current data and ongoing clinical trials of emerging therapies for the management of acute GVHD in the allogeneic HSCT population

Activity Faculty


Miguel-Angel Perales, MD

Chief, Adult Bone Marrow Transplantation Service
Memorial Sloan Kettering Cancer Center
Associate Professor, Medicine
Weill Cornell Medical College
New York, NY


Nelson J. Chao, MD, MBA

Donald D. and Elizabeth G. Cooke Professor
Chief, Division of Hematologic Malignancies and Cellular Therapy/BMT
Director, Global Cancer
Duke University
Durham, NC


Sung Won Choi, MD, MS

Professor, Pediatrics
Edith S Briskin and Shirley K Schlafer Research Professor
Blood and Marrow Transplantation Program
University of Michigan
Ann Arbor, MI


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources